During the secondary analysis, the a lot less conservative but clinically meaningful criterion of secure response (described being a 50% or more reduction in MADRS from baseline for 2 weeks) was used. Of your patients who achieved secure response, 25.8% during the esketamine group and fifty seven.six% within the placebo https://jimmym777jxl4.eqnextwiki.com/user